iclepertin

News

Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.

News

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.